Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261302 | 1.00 | EPHX1 (0.42) | EPHX1FAAHMAPTGMNNTP53 | |
| SCHEMBL9506073 | 0.81 | CPB2 (0.42) | EPHX1THRBBLMMEN1KMT2A | |
| SCHEMBL9509960 | 0.81 | CPB2 (0.38) | THRBBLMKMT2A | |
| SCHEMBL9509958 | 0.81 | CPB2 (0.38) | THRBBLMKMT2A | |
| SCHEMBL23042930 | 0.77 | — | — | |
| SCHEMBL10896691 | 0.77 | MAPT (0.43) | EPHX1MAPTGMNNTP53POLB | |
| SCHEMBL7208095 | 0.77 | MAPT (0.38) | EPHX1MAPTGMNNTP53POLB | |
| SCHEMBL7208119 | 0.77 | MAPT (0.38) | EPHX1MAPTGMNNTP53POLB | |
| SCHEMBL789713 | 0.71 | HSD17B10 (0.47) | EPHX1FAAHMAPTGMNNTP53 | |
| SCHEMBL6058015 | 0.70 | KDM4E (0.44) | MAPTTHRBBLMSMN1; SMN2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-0889036-B1 | HIV protease inhibitors | AGOURON PHARMA (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6693199-B2 | DEPROTECTING CARBAMATE GROUP AND AMIDATING IN PRESENCE OF SUCH AS HYDROXYBENZOTRIAZOLE HYDRATE PROMOTER | AGOURON PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030216569-A1 | Method of making HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1340744-A2 | Hiv protease inhibitors | Agouron Pharmaceuticals, Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6525215-B2 | As antiviral agents suitable for therapy of patients or hosts infected with the HIV virus, which is known to cause AIDS | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020077338-A1 | HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2002-06-20 | — | — | US | disclosed |
| US-6271235-B1 | VIRICIDE | AGOURON PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-6162812-A | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-5952343-A | VIRICIDES; SPECIFICITY; NONTOXIC | AGOURON PHARMACEUTICALS, INC. | 1999-09-14 | — | — | US | disclosed |
| EP-0744948-A1 | PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0741719-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5480887-A | FOR HIV, THIENO(3,2-C)PYRIDINE-(6S)-CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5461154-A | HIV protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995021164-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995020962-A1 | PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0604185-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077338-A1 | HIV protease inhibitors | PREP, PRSS1, SERPINB1 | EPHX1 1786/4885FAAH 929/4885MAPT 648/4885 |
| US-20030216569-A1 | Method of making HIV protease inhibitors | SERPINB1, PRSS1, PREP | EPHX1 1321/4885FAAH 814/4885MAPT 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.